These inhibitors specifically disrupt cancer cell viability, abrogate CtBP’s transcriptional function, and block polyp formation in a mouse model of intestinal polyposis that depends on CtBP’s oncogenic functions [22]. The gene discussed is CTBP1; the disease is gastrointestinal polyp.